%D8%B1%D9%8A%D9%88%D9%83%D9%8A%D8%BA%D9%88%D8%AA%D8%B1%DB%8C%D9%88%D8%B3%DB%8C%D9%82%D9%88%D8%A6%D8%A7%D8%AARiociguatRiociguat%D8%B1%DB%8C%D9%88%D8%B3%DB%8C%DA%AF%D9%88%D8%A6%D8%A7%D8%AARiociguat%D7%A8%D7%99%D7%95%D7%A1%D7%99%D7%92%D7%95%D7%90%D7%98Riociguat%E3%83%AA%E3%82%AA%E3%82%B7%E3%82%B0%E3%82%A2%E3%83%88RiociguatRiociguatQ2154494
about
P3781
Relative Bioavailability Study (2014-06-30)Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Renal Impairment and Healthy Participants Matched foStudy on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Mat
P4844
Chronic thromboembolic pulmonary hypertension: role of medical therapyRecent progress in the diagnosis and management of chronic thromboembolic pulmonary hypertensionEffects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockadeSoluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl ratsRiociguat for the treatment of chronic thromboembolic pulmonary hypertension.Riociguat for the treatment of pulmonary arterial hypertension.Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study.Pathways in pulmonary arterial hypertension: the future is here.The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in ratsRiociguat for interstitial lung disease and pulmonary hypertension: a pilot trial.First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension.Effects of different pulmonary vasodilators on arterial saturation in a model of pulmonary hypertension.Animal models related to congenital heart disease and clinical research in pulmonary hypertension.Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?Riociguat for the treatment of pulmonary hypertension.The chemistry and biology of soluble guanylate cyclase stimulators and activators.Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?Chronic post-embolic pulmonary hypertension: a new target for medical therapies?Soluble guanylate cyclase stimulators in pulmonary hypertension.Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.Riociguat for pulmonary hypertension--a glass half full.Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design.Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertensionHypertension: Riociguat therapy for pulmonary hypertension
P921
Q26825088-451308D8-BBA6-4D11-A172-75FD7DCC9F50Q26992258-9110445C-6BDD-4645-9B2F-2BF8A6F01A3BQ28482185-69D28076-D62C-4834-BB87-BADC328F697BQ28742463-7648C573-262E-410B-B5C7-8DB53E493D85Q33163081-B571AD29-5EBB-4FF4-9FA5-7788B9D5A986Q33163083-E8A9D16D-953B-4943-9FFB-556EC200B2A5Q33447738-D67DE66D-3522-450D-8ED0-1D81CD634A9EQ34314973-A4D4558D-FFE1-468D-B960-444B65C1078CQ34389618-1F5D3EAF-880F-4BFD-9ADF-5C91243CA2DBQ34641890-D5D3FED0-DE7E-4F00-8E24-45E9E791F611Q34917310-018B2BCA-92D8-4034-BF71-811BCF4B2E5FQ34981737-25EA9ED1-6FCF-43DA-A6EF-FA7A983BEA3CQ37737931-392F8C64-B877-4BFC-B817-EF2051D4D0C0Q37801162-3310206F-41A4-4EEA-9FC2-1FADB15EDCB5Q37851516-A8A9C286-6FFE-4503-8EE4-24A234895C83Q38130465-3087FE2F-59A2-4320-8C74-D968EAA50183Q38133487-1BBE2E12-5159-4657-9220-1CE120766980Q38133494-0E7C0D72-AB3D-4CD4-907A-12C2BE5E46B9Q38149032-2B2E210B-4D56-426A-AFD7-B249974E2D50Q38449826-0BE8F4BE-3373-4755-9F2B-F14F8E232AE6Q43728967-C4A1EDFE-1990-49CD-A230-59CD5B100D6DQ48425789-1BE9164C-F821-4E15-8828-913A157B9A24Q64249915-CCB7AADC-C54B-4A2D-858D-722D4AFA41FAQ87243855-39FF1FDA-ADBD-4936-B222-7716E4940E75
P921
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Riociguat
@de
Riociguat
@id
Riociguat
@nl
Riociguat
@sh
Riociguat
@sr
Riociguat
@vi
riociguat
@en
riociguat
@fr
ריוסיגואט
@he
ريوكيغوت
@ar
type
label
Riociguat
@de
Riociguat
@id
Riociguat
@nl
Riociguat
@sh
Riociguat
@sr
Riociguat
@vi
riociguat
@en
riociguat
@fr
ריוסיגואט
@he
ريوكيغوت
@ar
altLabel
Adempas®
@en
BAY 63-2521
@en
Methyl N-(4,6-diamino-2-{1-((2 ...... imidin-5-yl)-N-methylcarbamate
@en
Methyl N-[4,6-Diamino-2-[1-[(2 ...... imidinyl]-N-methyl-carbaminate
@en
Riociguat
@en
Riociguatum
@en
prefLabel
Riociguat
@de
Riociguat
@id
Riociguat
@nl
Riociguat
@sh
Riociguat
@sr
Riociguat
@vi
riociguat
@en
riociguat
@fr
ריוסיגואט
@he
ريوكيغوت
@ar
P2175
P486
P592
P6366
P661
P662
P665
P683
P1579
P2067
P2115
N0000188995